EPHB2 and neoplasm: In this study, we engineered Eb2Mab-12 into a mouse IgG2a-type (Eb2Mab-12-mG2a) and a human IgG1-type (Eb2Mab-12-hG1) mAbs, and evaluated antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antitumor efficacy in EphB2-positive tumor xenograft models.